ABSTRACT. Brain natriuretic peptide (BNP) is used as a marker of cardiac dysfunction to predict heart failure mortality. The significance of the prognostic ability of BNP for liver cirrhosis remains unknown, although the levels of BNP seen in cirrhosis are high. We aimed to determine whether the BNP level is related to the stage of cirrhosis and could serve as a prognostic marker of cirrhosis (predict the 1-year all-cause mortality). We recruited 92 patients at different stages of cirrhosis and 81 controls matched by age and gender for this study. At admission, cardiac physical examination and BNP measurements were performed. Upon discharge, the 89 patients were followed up for 12 months. The median BNP levels of patients with cirrhosis were 167.0 pg/mL, which were significantly higher than those of the control group (167.0 vs 34.8 pg/mL, P = 0.001). Serum BNP levels were positively correlated with the Child score, the grade of esophageal varices, a history of spontaneous bacterial peritonitis, and the presence of ascites 5189 B-type natriuretic peptide and cirrhosis progression ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 5188-5196 (2015) and collateral circulation. BNP levels above the median were associated with an increased occurrence of death within 12 months of discharge (log rank P = 0.025), as determined by univariate and multivariate Cox regression analyses. Esophageal varices, large/medium volume ascites, and BNP levels were related to the clinical outcome (P = 0.034, 0.030, and 0.025, respectively). Together, these results suggested that serum BNP levels are significantly correlated with the stage of cirrhosis, suggesting that BNP levels might serve as a significant predictor for 1-year all-cause mortality.
INTRODUCTION
Brain-natriuretic peptide (BNP) is a cardiac hormone secreted from the ventricle in response to pressure or volume overload (Maeda et al., 1998) . High BNP levels correlate with left ventricular dysfunction and its prognosis (Chang et al., 2013; Geske et al., 2013) . However, high levels of BNP also have been found in congestive states such as heart and renal failure and in chronic liver disease (Passino et al., 2008) . Previous studies have shown increased plasma concentrations of BNP in some patients with cirrhosis (Woo et al., 2008; Pimenta et al., 2010) , which suggested that cardiac dysfunction might also be present. Recently, several studies have documented that BNP levels were related to the severity of disease in these patients, indicating its predictive value for concomitant cardiac dysfunction and cirrhosis progression (Yildiz et al., 2005) . However, the role of BNP as a prognostic marker in that setting has not been fully explored. The aim of our study was to determine the association of BNP levels with the clinical severity of liver cirrhosis (according to the Child-Pugh classification and the associated complications) and to evaluate the significance of BNP as a medium-term prognostic marker in this setting.
MATERIAL AND METHODS

Subjects
From April 2008 to September 2010, 92 patients with cirrhosis from the First Affiliated Hospital of Wenzhou Medical University were consecutively included in this study. They consisted of 64 men and 28 women with a median age of 57 years (range, 29-75 years). Diagnoses were based on established clinical, biochemical, and ultra-sonographic criteria. Patients who had diseases affecting BNP levels such as hypertension, diabetes, coronary heart disease, hematopathy, any other major disease, or oral contraceptive use were excluded from the study.
The control group comprised 81 subjects without liver disease, with similar age and gender distributions. All controls had normal arterial blood pressure and no signs of major organic disease. All patients and controls had normal cardiac physical examination, and those who had a chest X-ray demonstrating signs of cardiomegaly were excluded. Electrocardiograms (ECGs) showed normal configurations apart from sporadic extra systoles in some patients. The demographic features of patients, etiological factors, and clinical information were collected. The clinical and biochemical data are summarized in Table 1 . This study was conducted in accordance with the Declaration of Helsinki and with approval from the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from all participants.
Biochemical analysis
Blood was drawn from a forearm vein in the morning following a 12 h fast and it was collected in standard ethylene diamine tetraacetic acid tubes for BNP measurement, and in the appropriate tubes for other laboratory determinations including liver and renal function tests, blood count, and prothrombin time [PT, as reflected by the international normalized ratio (INR)], performed using standard laboratory automated techniques. The BNP concentration was measured by a sensitive method based on the use of antibodies labeled with a fluorescent dye (BNP-TRIAGE, Biosite Diagnostics, San Diego, CA, USA). This is a rapid assay with a measurement time of approximately 15 min for a single sample, and the test results are calculated automatically. The coefficient of variation for BNP is 10.9%. The measurement range of this assay is 10-5000 pg/mL and it is designed to have an upper 95%CI of 12% total coefficient of variation.
The stage of cirrhosis was classified according to the Child-Pugh classification, which reflects the severity of the disease. Esophageal varices were detected by endoscopic examination and graded with Paget classification (Sleisenger et al., 1998) . Portal-splenic vein diameter was measured using a Doppler-ultrasonography device (ALT-HDI 3500, Philips, USA).
Patients were followed up for 12 months from discharge day to evaluate the incidence and etiology of all-cause mortality. The primary endpoint was all-cause death. Surveillance was made by direct contact with patients or relatives and observation of medical records, by an investigator blinded to the laboratory BNP results.
Statistics analysis
Data are reported as median (25th-75th percentile) for quantitative variables and as N (%) for categorical variables, and was analyzed using the SPSS version 13.0 software (SPSS, Chicago, IL, USA). One way analysis of variance (ANOVA) with Tukey's post hoc pairwise multiple comparison procedure was used. In cases of non-normality, the Kruskal-Wallis test (with Dunn's pairwise comparison) was applied. Correlations were performed by the Pearson regression analysis or in the case of non-linearity by the Spearman-Rank test. Multiple regression analysis was performed to evaluate the relation between BNP and pertinent clinical and biochemical parameters, and with the presence of complications. A stepwise forward modelbuilding approach was employed to evaluate the effects of all variables initially examined. Next, the covariates most probably associated with the survival time in days were investigated by using the Kaplan-Meier (KM) estimator. The significance of the survival was examined by the log-rank test. The association of independent variables with time to clinical outcome was assessed by Cox regression analysis and was expressed as a hazard ratio (HR) and 95%CI. A P < 0.05 was considered to be statistically significant.
RESULTS
Subject data
study. Of those, two patients died during hospitalization and were excluded. The median age of the study population was 57 years (range, 29-75 years), including 73 men and 19 women. The causes of cirrhosis were hepatitis B virus infection-associated post-hepatic cirrhosis in 65 patients, hepatitis C virus infection in one, alcoholism in 12, autoimmune disorder in two, and secondary cirrhosis in four. Among them, 21 patients exhibited ascites, 23 experienced recent gastrointestinal bleeding, 10 had encephalopathy above grade I, and 9 experienced spontaneous bacterial peritonitis. The clinical features of the subjects are shown in Table 1 . 
BNP and Child-Pugh classification
The BNP levels of patients with hepatic cirrhosis were significantly higher than those in the control group (HR = 167.0, 95%CI: 32.3-652.6 vs HR = 34.8, 95%CI: 10.0-72.4); P = 0.001). There was also a significant difference among the patients with cirrhosis after classifying them according to Child-Pugh classification, with Child class B and C patients exhibiting significantly higher BNP levels than class A patients (P = 0.041, 0.032, respectively; Table 2) BNP and complications of cirrhosis BNP concentrations were significantly higher in patients who had ascites, esophageal varices, or a history of spontaneous bacterial peritonitis or of hepatic encephalopathy compared with patients without these complications (P < 0.05, respectively). Although the BNP levels of the patients with cirrhosis who had a history of variceal bleeding or portal vein thrombosis were higher than those in the patients without them, there was no statistical difference between the BNP levels of the two patient groups (P = 0.08, 0.12, respectively). The presence of collateral circulation was diagnosed by physical examination or Doppler ultrasonography, and it was observed to also be related to high BNP levels (P = 0.041). Patients with esophageal varices had significantly higher BNP levels than did patients without them (OR = 163.7, 95%CI: 60.5-309.5) vs OR = 116.7, 95%CI: 51.2-283.1; P = 0.045). Although BNP levels increased with higher grades of esophageal varices, no significant difference was observed between groups of patients with cirrhosis classified according to variceal size (P = 0.067) in post hoc analyses; BNP levels of patients with varices are shown in Table 3 . BNP was not related to the QTc interval (r = 1.21, P = 0.896), although levels in patients with cirrhosis on treatments of beta-blockers and diuretics were significantly higher than those in patients without these treatments (Table 4) . 
BNP and prognosis
During the follow-up period, 11 patients died (six of hemorrhage, two of portosystemic encephalopathy, two of infections, and one of liver failure) and two were lost to follow-up. In univariate Cox regression analysis, more than one factor was shown to be related to outcome, including age, BNP level, esophageal varices, total bilirubin, hepatic encephalopathy history, and large/medium ascites volume (Table 5 ); in contrast, in multivariate analysis, only three factors were flagged as independent predictors of survival at 12 months: BNP levels, esophageal varices, and large/medium volume ascites (Table 6 ). BNP levels dichotomized according to the median (167 pg/mL) were associated with the occurrence of all-cause mortality at 12 months of followup, as evaluated by Kaplan-Meier analysis (log rank test P = 0.023) (Figure 1 ). The BNP levels at hospital admission of patients with decompensated cirrhosis dichotomized according to the median (167 pg/mL) were associated with the occurrence of all-cause mortality at twelve months of follow-up, as evaluated by KaplanMeier analysis (log rank test P = 0.025).
DISCUSSION
Our results showed that: first, serum BNP levels were significantly increased in patients with cirrhosis compared with controls; second, BNP concentrations were related to the severity of cirrhosis according to Child-Pugh classification and the decompensation component of cirrhosis; and third, BNP levels were associated with medium-term survival, implying its potential utility as a prognostic predictor in cirrhosis.
Several earlier studies have shown high BNP levels in chronic liver disease, and our study also confirms previous findings that the BNP levels of healthy individuals and of patients with cirrhosis differ. On the other hand, we found an association between BNP levels and the Child-Pugh score, wherein Child C and B groups had higher BNP levels than did the Child A group, which in turn had higher BNP levels than did the control group in our study. These findings are supported by those of Henriksen et al. (2003) , and indicate that BNP might be an early indicator of cirrhosis in patients with hepatocellular diseases and might also be related to the severity of cirrhosis.
According to the results of this study, the existence of ascites, collateral circulation, a history of spontaneous bacterial peritonitis, and esophageal varices were related to increased BNP levels. Although there was a lack of statistical significance, higher variceal grades tended to be present together with higher BNP levels. These findings are indicators of high portal vein pressure, and cirrhotic patients with portal hypertension had significantly higher BNP levels than did patients without portal hypertension according to the results of this study. These findings indicate that BNP might be also a prediction tool to follow the clinical progress of patients with cirrhosis. BNP might also be used for pursuing the responses to the treatment given to these patients. However, further studies are needed in order to reveal the relationship between BNP and treatment modalities in patients with cirrhosis.
We also discovered that the BNP levels of patients on treatments with beta-blockers and diuretics were significantly higher than those of patients without treatment, which is not associated with clinical experience. de Lemos et al. (2003) and some others have advocated that the net effect of beta-blockers and diuretics is often to reduce BNP concentrations (Park et al., 2010; Luchner et al., 2013) . In cirrhotic cardiomyopathy, beta adrenergic receptor and plasma membrane dysfunction are observed in addition to an increase in intracardiac volume; therefore, diuretics and beta-blockers likely decrease BNP levels in patients with decompensated heart failure (Johnson et al., 2002) by improving hemodynamic parameters and the left ventricular ejection fraction (Møller and Henriksen, 2002; Fujimura et al., 2009) , thus reducing intracardiac pressure and sodium retention and consequently decreasing the secretion of BNP. However, we draw the opposite conclusion in this study from our results than did Yilmaz et al. (2010) , who surmised that these findings might be a result of a selection bias, because the probable underlying cause of increased levels of BNP in patients using beta-blockers and diuretics might be that these patients were more likely to suffer from volume overload, and that these medications are usually given in these patients. However, the underlying cause of the increased BNP levels seen in patients with cirrhosis is still unknown. Several factors can be assumed to be responsible: 1) altered hepatic (or renal) degradation; 2) increased heart secretion as a result of hyperkinetic circulation and/or latent subclinical heart failure-cirrhotic cardiomyopathy; or 3) the consequence of resistance to natriuretic peptides. Most studies have reported that increased BNP levels in patients with cirrhosis were associated with cardiac systolic function. Henriksen et al. (2003) reported that BNP levels were related to markers of cardiac dysfunction, such as QT interval, heart rate, and plasma volume. In contrast to previ-ous studies (Padillo et al., 2010; Bernal et al., 2012) , there was no relationship between BNP concentration and QTc interval identified in our research. It has been reported that a level of BNP over 500 pg/mL is diagnostic for the congestive heart failure presented and diagnosed by a lower ejection fraction on echocardiographic examination (Buğdaycı and Sökmen, 2012) . As the BNP levels in our study were almost below 500 pg/mL, this might suggest that the increased BNP levels were not associated with any cardiac dysfunction in our patients; also, because we did not find any relationship between the serum sodium and BNP levels, the elevated BNP levels might be instead associated with liver failure. In this study, we found that a history of hepatic encephalopathy and spontaneous bacterial peritonitis were related to increased BNP levels in patients with cirrhosis. Ascites and hepatic encephalopathy are part of the parameters of the Child-Pugh classification that indicate the severity of liver disease; the results of our study suggested that the presence of these were related to increased BNP levels.
Decompensated cirrhosis is a condition with grim prognosis. While death in patients with cirrhosis generally occurs because of end-stage liver failure or portal hypertension, in a multivariate Cox regression mode, ascites, esophageal varices, and BNP levels were all independent predictors of outcome. Ascites confers a poor prognosis because of the associated development of spontaneous bacterial peritonitis and hepatorenal syndrome. We found that BNP was an independent predictor in multivariate Cox regression analysis, similar to previous results (Pimenta et al., 2010) . BNP concentrations in patients with cirrhosis have been reported to be an independent predictor of medium-term (6-month) survival in hospitalized patients with decompensated cirrhosis, suggesting its utility in risk stratification of patients with advanced cirrhosis (Pimenta et al., 2010) ; this finder also was supported by the results of Saner et al. (2011) . This finding was not unexpected because, as mentioned above, increased BNP concentrations were found to be associated with the decompensation components of cirrhosis such as hepatic encephalopathy, esophageal varices, and ascites. As is well recognized, esophageal variceal bleeding is a major cause of death in cirrhosis (Krishnan et al., 2012) , and hepatic encephalopathy is also a leading cause of death. BNP is a known marker of cardiac systolic function; however, as was also the case with our patients, BNP levels can be influenced by other hemodynamic variables as well as non-cardiac-related parameters such as age, renal function, hemoglobin, and even albumin, a marker of liver failure (Huh et al., 2012) . Taken together, therefore, it appears plausible that BNP levels might serve as a mirror of this complex milieu, and might be of prognostic usefulness in patients with cirrhosis.
In conclusion, serum BNP levels were found to correlate significantly with the stage of cirrhosis in our study. BNP levels also were seen to be a significant predictor for 1-year all-cause mortality, indicating that measurements of BNP might be a simple and valuable diagnostic test for the prediction of the mortality of patients with decompensated cirrhosis.
